Prevail Therapeutics Inc (PRVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 202,095 | N/A | N/A | N/A | N/A |
| TOTAL | $206,348 | $N/A | $N/A | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 2,123 | N/A | N/A | N/A | N/A |
| Other Non-Current Assets | 7,607 | 0 | 0 | 0 | 0 |
| TOTAL | $9,730 | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $216,078 | $N/A | $N/A | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,003 | 0 | 0 | 0 | 0 |
| Accrued Expenses | 4,555 | N/A | N/A | N/A | N/A |
| TOTAL | $7,659 | $N/A | $N/A | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 7,380 | 0 | 0 | 0 | 0 |
| TOTAL | $7,380 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $15,039 | $N/A | $N/A | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 34,021 | N/A | N/A | N/A | N/A |
| Common Shares | 3 | N/A | N/A | N/A | N/A |
| Retained earnings | -45,962 | N/A | N/A | N/A | N/A |
| TOTAL | $201,039 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $216,078 | $0 | $0 | $0 | $0 |